Hospital
Mark Twain Medical Center
Mark Twain Medical Center was paid $10.57M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is 0450, Emergency room services — 42% of everything it billed.
33Billing provider infoMARK TWAIN MEDICAL CENTER
SAN ANDREAS, CA 95249
SAN ANDREAS, CA 95249
33aNPI1508968819assigned 09/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.57M
24GClaims253,217
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#177 of 410
Median peer was paid$6.90M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,194 | $1.54M | |
| 2019 | 37,308 | $1.57M | |
| 2020 | 29,687 | $1.23M | |
| 2021 | 31,406 | $1.42M | |
| 2022 | 34,895 | $1.56M | |
| 2023 | 45,302 | $1.84M | |
| 2024incomplete | 37,425 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 42% | 17,694 | 15,954 | $4.42M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 8,600 | 2,757 | $486K |
| 99199 | Unlisted special service, procedure or report | 2.8% | 4,434 | 4,041 | $292K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.6% | 1,818 | 1,816 | $274K |
| 80053 | Comprehensive metabolic panel | 2.4% | 16,689 | 15,708 | $253K |
| A9150 | Non-prescription drugs | 2.0% | 2,273 | 1,185 | $209K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 3,780 | 3,509 | $189K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 8,302 | 8,156 | $188K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 1,514 | 1,464 | $169K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 3,264 | 2,961 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 20,799 | 19,088 | $165K |
| A9270 | Non-covered item or service | 1.5% | 3,099 | 1,766 | $161K |
157 more codes
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.3% | 2,984 | $140K |
| 80061 | Lipid panel | 1.3% | 7,792 | $139K |
| J3490 | Unclassified drugs | 1.3% | 3,446 | $137K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.3% | 2,127 | $137K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 9,374 | $119K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,536 | $119K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 1,220 | $119K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 2,895 | $113K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.0% | 2,129 | $108K |
| 76830 | Ultrasound, transvaginal | <1% | 919 | $90K |
| 97750 | <1% | 662 | $83K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,406 | $82K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,548 | $77K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,792 | $75K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,901 | $72K |
| 76641 | <1% | 583 | $70K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,014 | $69K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 679 | $68K |
| 97139 | <1% | 1,029 | $68K | |
| 99283 | Emergency room visit (moderate) | <1% | 533 | $63K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,281 | $61K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,406 | $60K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,951 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,341 | $56K |
| 84439 | <1% | 4,063 | $56K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 459 | $55K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 867 | $55K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,807 | $55K |
| 0510 | <1% | 1,072 | $54K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,199 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,267 | $48K |
| G0378 | Hospital observation service, per hour | <1% | 989 | $47K |
| 81001 | <1% | 9,635 | $46K | |
| 73030 | <1% | 1,094 | $43K | |
| Z7502 | <1% | 1,057 | $39K | |
| 87088 | <1% | 2,821 | $33K | |
| 99284 | Emergency room visit (serious) | <1% | 235 | $30K |
| 72100 | <1% | 631 | $29K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 462 | $28K |
| 83880 | <1% | 2,086 | $26K | |
| 73630 | <1% | 594 | $24K | |
| 87634 | <1% | 1,321 | $24K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,892 | $23K |
| 87081 | <1% | 985 | $22K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 310 | $21K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,595 | $21K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 482 | $21K |
| 80076 | <1% | 3,838 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 672 | $18K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,614 | $17K |
| 0250 | <1% | 8,067 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 123 | $16K |
| J2704 | Injection, propofol, 10 mg | <1% | 63 | $16K |
| 87430 | <1% | 628 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 306 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 453 | $14K |
| 81025 | <1% | 2,313 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 454 | $13K |
| 73562 | <1% | 322 | $13K | |
| 73130 | <1% | 316 | $12K | |
| 87186 | <1% | 1,586 | $12K | |
| 0760 | <1% | 227 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 228 | $12K |
| 0710 | <1% | 250 | $11K | |
| 82607 | <1% | 904 | $11K | |
| 87077 | <1% | 1,250 | $11K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 219 | $11K |
| 86140 | <1% | 1,699 | $11K | |
| 27096 | <1% | 21 | $11K | |
| 85610 | <1% | 3,408 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 153 | $10K |
| 82728 | <1% | 509 | $10K | |
| 84484 | <1% | 2,813 | $9K | |
| 82746 | <1% | 369 | $8K | |
| 83540 | <1% | 891 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 106 | $8K |
| 85018 | <1% | 2,096 | $8K | |
| 83690 | <1% | 3,364 | $8K | |
| 85730 | <1% | 2,432 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $7K |
| 81002 | <1% | 1,869 | $7K | |
| 84153 | <1% | 253 | $7K | |
| 84466 | <1% | 356 | $6K | |
| 84481 | <1% | 281 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 193 | $6K |
| 73564 | <1% | 124 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 221 | $6K |
| 72040 | <1% | 141 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 621 | $6K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 107 | $6K |
| 87070 | <1% | 504 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 84 | $5K |
| 85651 | <1% | 1,063 | $5K | |
| 0270 | <1% | 668 | $5K | |
| 73110 | <1% | 112 | $5K | |
| 85027 | <1% | 654 | $5K | |
| 83735 | <1% | 1,037 | $4K | |
| 86803 | <1% | 183 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 411 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 51 | $3K |
| 73502 | <1% | 54 | $3K | |
| 84403 | <1% | 65 | $3K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 52 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 174 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| 82043 | <1% | 252 | $2K | |
| 92551 | <1% | 82 | $2K | |
| 83605 | <1% | 855 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 185 | $2K |
| 73610 | <1% | 41 | $2K | |
| 90715 | <1% | 41 | $2K | |
| 86710 | <1% | 72 | $1K | |
| 87040 | <1% | 406 | $1K | |
| 86780 | <1% | 124 | $1K | |
| 86038 | <1% | 92 | $1K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 12 | $1K |
| 96127 | <1% | 168 | $1K | |
| 73600 | <1% | 27 | $1K | |
| 96376 | <1% | 119 | $837.15 | |
| 82150 | <1% | 255 | $799.63 | |
| 85652 | <1% | 239 | $763.41 | |
| 86430 | <1% | 75 | $721.59 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 241 | $720.49 |
| 87340 | <1% | 38 | $708.94 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $666.34 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 24 | $640.78 |
| 94729 | <1% | 13 | $610.35 | |
| 94060 | <1% | 13 | $605.86 | |
| 93971 | <1% | 13 | $587.39 | |
| 80074 | <1% | 12 | $579.26 | |
| 94726 | <1% | 13 | $542.36 | |
| 82962 | <1% | 29 | $520.88 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $446.60 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $436.13 |
| 77080 | <1% | 13 | $416.76 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 204 | $402.72 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 24 | $360.38 |
| 99173 | <1% | 91 | $332.86 | |
| 84145 | <1% | 124 | $329.20 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 103 | $286.01 |
| 86039 | <1% | 29 | $250.00 | |
| 83655 | <1% | 25 | $195.09 | |
| 82550 | <1% | 27 | $178.19 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12 | $172.82 |
| 86160 | <1% | 12 | $159.24 | |
| 82248 | <1% | 13 | $95.42 | |
| 84550 | <1% | 14 | $84.93 | |
| 85007 | <1% | 64 | $73.48 | |
| 72020 | <1% | 54 | $44.18 | |
| 76000 | <1% | 25 | $41.28 | |
| 84703 | <1% | 28 | $15.87 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13 | $9.19 |
| 0370 | 0% | 16 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| 0253 | 0% | 60 | $0.00 | |
| 0272 | 0% | 25 | $0.00 | |
| 0360 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHIVERS, JOHN (CHIEF FINANCIAL OFFICER)